Trial Profile
Phase II randomized multicenter study of multiple doses of palonosetron plus aprepitant versus multiple doses of palonosetron alone in preventing chemotherapy-induced nausea and vomiting in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome receiving multiple days chemotherapy
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Feb 2017
Price :
$35
*
At a glance
- Drugs Palonosetron (Primary) ; Aprepitant
- Indications Chemotherapy-induced nausea and vomiting
- Focus Therapeutic Use
- 03 Mar 2014 New trial record